Sanofi to Acquire Provention Bio for $2.9 Billion

Sanofi Acquires Translate Bio in $3.2 Billion Deal

August 3, 2021

Biotechnology

Sanofi SA has entered into a definitive agreement to acquire all outstanding shares of clinical-stage mRNA therapeutics company Translate Bio for about $3.2 billion, or $38.00 per share in cash. The acquisition is intended to accelerate Sanofi’s application of messenger RNA (mRNA) to develop therapeutics and vaccines, building on an existing mRNA collaboration.

Sanofi to Acquire Vicebio for Up to $1.6 Billion

July 25, 2025

Healthcare Services

Sanofi has entered an exclusive, definitive agreement to acquire biopharmaceutical company Vicebio for up to US$1.6 billion, comprising a US$1.15 billion upfront payment plus up to US$450 million in development and regulatory milestones. The deal is aimed at accelerating Vicebio’s next-generation respiratory virus vaccine platform, including lead candidate VXB-241 targeting RSV and hMPV.

Sanofi to Acquire Blueprint Medicines to Expand Rare Immunology Pipeline

June 2, 2025

Pharmaceuticals

Sanofi and Blueprint Medicines entered into an agreement under which Sanofi will acquire Blueprint via a cash tender offer and subsequent merger. The deal values Blueprint at $129.00 per share in cash (approximately $9.1 billion equity value), with additional potential milestone payments tied to BLU-808 via a contingent value right.

Novartis to Acquire MorphoSys in $2.9 Billion Deal

February 7, 2024

Pharmaceuticals

Novartis agreed to a voluntary public takeover offer to acquire MorphoSys AG for €68 per share, valuing the deal at about €2.7 billion (reported as $2.9 billion). The acquisition is intended to expand and complement Novartis’ oncology pipeline, including pelabresib (CPI-0610) and tulmimetostat (CPI-0209).

Servier Acquires Day One Biopharmaceuticals for About $2.5 Billion

March 6, 2026

Pharmaceuticals

Servier entered into a definitive agreement to acquire Day One Biopharmaceuticals, a commercial-stage biopharmaceutical company, in a cash deal valued at about $2.5 billion. Servier will pay $21.50 per share and expects the transaction to close in the second quarter of 2026, subject to customary regulatory approvals and tender conditions.

Merck Acquires Prometheus Biosciences

June 16, 2023

Healthcare Services

Merck (MSD outside the United States and Canada) entered into a definitive agreement to acquire Prometheus Biosciences for $200 per share in cash, valuing the equity at approximately $10.8 billion. The acquisition was expected to close in the third quarter of 2023, and Merck later announced completion of the deal, making Prometheus a wholly owned subsidiary.